HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.

Abstract
In models of triple-negative breast cancer (TNBC), it has recently been shown that the epidermal growth factor receptor (EGFR) pathway is up-regulated in the aldehyde dehydrogenase 1 (ALDH1)-positive cancer stem cell fraction. Because high-grade serous ovarian carcinoma (HGSC) reveals strong molecular similarities to TNBC, we aimed to investigate the potential link between ALDH1 and EGFR in this entity. Expression of ALDH1 was investigated in 131 primary HGSCs using immunohistochemistry. Expression data were correlated with EGFR expression as well as with clinicopathologic parameters and survival. Forty-two carcinomas (32.1%) were positive for ALDH1 protein expression. Data on EGFR expression were available for 112 tumors. In these cases ALDH1 was significantly linked to EGFR expression (P < .0001). ALDH1 positivity was a significant negative prognostic factor for overall survival both in univariate (P = .010) and in multivariate survival analyses (P = .041). Tumors that were positive for both ALDH1 and EGFR had an exceptionally bad prognosis as compared with carcinomas with 1 or both markers negative in univariate analysis (P < .0001) and in the multivariate setting (P = .004). Our study suggests that similar to TNBC, there is a link between ALDH1 and EGFR expression in HGSC. Double positivity for both markers identifies a subgroup of highly aggressive, poor-prognosis cancers for which alternative treatment options-potentially EGFR-targeting drugs-should be evaluated.
AuthorsCatarina Alisa Liebscher, Judith Prinzler, Bruno Valentin Sinn, Jan Budczies, Carsten Denkert, Aurelia Noske, Jalid Sehouli, Elena Ioana Braicu, Manfred Dietel, Silvia Darb-Esfahani
JournalHuman pathology (Hum Pathol) Vol. 44 Issue 8 Pg. 1465-71 (Aug 2013) ISSN: 1532-8392 [Electronic] United States
PMID23465277 (Publication Type: Journal Article)
CopyrightCopyright © 2013 Elsevier Inc. All rights reserved.
Chemical References
  • Biomarkers, Tumor
  • Isoenzymes
  • Aldehyde Dehydrogenase 1 Family
  • ALDH1A1 protein, human
  • Retinal Dehydrogenase
  • ErbB Receptors
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Aldehyde Dehydrogenase 1 Family
  • Biomarkers, Tumor (analysis)
  • Cystadenocarcinoma, Serous (metabolism, mortality, pathology)
  • ErbB Receptors (analysis, biosynthesis)
  • Female
  • Humans
  • Immunohistochemistry
  • Isoenzymes (analysis, biosynthesis)
  • Kaplan-Meier Estimate
  • Middle Aged
  • Neoplasm Grading
  • Ovarian Neoplasms (metabolism, mortality, pathology)
  • Prognosis
  • Proportional Hazards Models
  • Retinal Dehydrogenase (analysis, biosynthesis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: